BELLUS Health Inc. (BLU:TSX) Analyst rate as a Strong Buy

STA Research
by: STA Research
BELLUS Health Inc.

Based on the BELLUS Health stock forecast from 1 analyst, the average analyst target price for BELLUS Health stock is CAD 16.00 over the next 12 months. BELLUS Health Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BELLUS Health stock is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, BLU stock price was CAD 15.11BLU stock price has changed by +0.04% over the past week, +3.32% over the past month and +256.37% over the last year.

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

What we like:

High market capitalization:

BELLUS Health stock is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns:

BELLUS Health stock has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.

 

What we don’t like:

High volatility:

The total returns for BELLUS Health stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in BLU stock.

Overpriced compared to book value:

BELLUS Health stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow:

BLU stock price forecast has shown that the company had negative total cash flow in the most recent four quarters.

Negative free cash flow:

BLU stock price forecast has shown that the company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth:

BELLUS Health stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth:

BELLUS Health stock has shown below median revenue growth in the previous 5 years compared to its sector

Disclaimer

Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.